Soligenix, Inc. (SNGX)

Soligenix's stock price has significantly declined over the past year. In July 2025, Soligenix reported promising Phase 2a results for SGX945 in Behçet's Disease and highlighted strong results from a "real-world" trial of HyBryte for CTCL. In August 2025, the company received a notice from Nasdaq due to non-compliance with the minimum stockholders' equity requirement. In September 2025, Soligenix announced the closing of a public offering, raising $7.5 million, and the expansion of its European Medical Advisory Board for Cutaneous T-Cell Lymphoma. In October 2025, Soligenix achieved an important safety milestone in its confirmatory Phase 3 clinical trial of HyBryte for CTCL. In November 2025, Soligenix reported Q3 2025 earnings, with an EPS of -$0.58, and announced achieving an enrollment milestone for the planned interim analysis in the confirmatory Phase 3 clinical trial of HyBryte for CTCL.

The provided information does not contain specific details about the demand seasonality for Soligenix, Inc.'s products and services. Demand is likely driven by disease prevalence, clinical trial outcomes, regulatory approvals, and public health needs rather than typical seasonal consumer patterns.

Soligenix, Inc. is a late-stage biopharmaceutical company based in Princeton, New Jersey, focused on developing and commercializing products for rare diseases with unmet medical needs, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industry. The company's pipeline is divided into Specialized BioTherapeutics, focusing on treatments for inflammatory diseases and cancers such as SGX301 (HyBryte), SGX942 (dusquetide), SGX945, and SGX302, and Public Health Solutions, dedicated to developing biodefense vaccines and therapeutics such as RiVax, SGX943, ThermoVax, CiVax, and vaccine programs targeting filoviruses.

Soligenix, Inc. focuses on developing and commercializing products primarily in the United States and is headquartered in Princeton, New Jersey. The company has expanded its European Medical Advisory Board for Cutaneous T-Cell Lymphoma, indicating a potential future focus or interest in the European market for HyBryte.

Information directly detailing Soligenix's brand reputation in the past year is not explicitly available. Positive impacts include positive clinical trial results for HyBryte in CTCL, promising Phase 2a results for SGX945 in Behçet's Disease, a successful public offering raising $7.5 million, expansion of the European Medical Advisory Board for CTCL, and publication describing the extended stability of ebolavirus vaccines using its ThermoVax platform. Negative impacts include a significant decline in stock price, receiving a notice from Nasdaq due to non-compliance with the minimum stockholders' equity requirement, and potential dilution for existing shareholders due to the recent public offering and warrant adjustments.

Soligenix, Inc. has a mixed ownership structure, including institutional, insider, and retail investors. Institutional investors own approximately 3.60% to 13.78% of the stock, with major holders including Armistice Capital, Llc, and DRW Securities, LLC. Insiders own approximately 3.86% to over 1000% of the company's stock, with Claudio Cavazza being the largest individual shareholder. The general public, mostly retail investors, holds a substantial stake, with some reports indicating around 71% or 92.07% of the company.